Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current Phase 1 plan Publication to be …
Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing
Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models Novel RNA spliceosome-targeting payload PH1 shows …
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC
CEO Abizer Gaslightwala discusses the Company’s strategic partnership with WuXi XDC and its implications for platform validation and development …
Akari Therapeutics Announces Strategic Partnershipwith WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
Strategic Partnership Enables Akari to Accelerate IND Filing By Late 2026 TAMPA, FL and LONDON – April 6, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an …
Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
TAMPA, FL and LONDON – March 18, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) …
